Stay updated on Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial
Sign up to get notified when there's something new on the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page.

Latest updates to the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page
- CheckyesterdayChange DetectedThe web page has added significant information regarding drug safety and specific medical conditions, including details about dalfampridine and resources related to Neuromyelitis optica, while removing various location-related terms and some pharmacological categories.SummaryDifference7%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check29 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1%
- Check36 days agoChange DetectedThe web page has updated its version from v2.16.6 to v2.16.8, indicating a new release of the content or software. Additionally, a section on HHS Vulnerability Disclosure has been added.SummaryDifference0.2%
- Check43 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
Stay in the know with updates to Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page.